Paralytic shellfish poisoning 机翻标题: 暂无翻译,请尝试点击翻译按钮。

源语言标题
(JP6196638) 麻痺​性​貝​毒
公开号/公开日
JP6196638 B2 2017-09-13 [JP6196638]JP2015509971 A 2015-04-02 [JP2015509971] / 2017-09-132015-04-02
申请号/申请日
2014JP-0561471 / 2013-03-15
发明人
;
申请人
ARGENIS SPL;
主分类号
IPC分类号
A61K-009/06A61K-009/107A61K-009/12A61K-009/127A61K-009/70A61K-031/192A61K-031/196A61K-031/4402A61K-031/4545A61K-031/519A61K-031/573A61K-047/08A61K-047/10A61K-047/12A61K-047/14A61K-047/16A61K-047/18A61K-047/20A61K-047/22A61K-047/24A61K-
摘要
(JP6196638) The invention concerns a paralytic shellfish poison for the treatment of itching in a human being or another mammal.  (From EP2638908 A1)
机翻摘要
暂无翻译结果,您可以尝试点击头部的翻译按钮。
地址
代理人
代理机构
;
优先权号
2012EP-0159932 2012-03-16 2012US-61613601 2012-03-21 2013WO-EP55448 2013-03-15
主权利要求
(JP6196638) 1. To a human or other mammal in the topical treatment of itching of paralytic shellfish poisoning for use in the method (PSP) pharmaceutical compositionor, where PSP is, (I) the following formula:  ˜C, R1 and R5 is independently, selected from the group consisting - OH and -H and; R2 and R3 is independently, - H, - OSO3- and - SO3 is selected from the group consisting of; and R4 is, - H, - OH, - OC (=O) NH2 、-OC(=O) NHSO3- - OC (=O) and CH3 is selected from the group consisting of, professional pinot perhydronaphthyl pudding saxitoxin represented by either Formula 3, 4 - or tricyclic ring, or the PSP, professional pinot perhydronaphthyl pudding saxitoxin is a salt of a tricyclic or 3, 4 -, wherein pharmaceutical composition.  2. R2 and R3 either one of - OSO3- FPAs, or R4 is - OC (=O) NHSO3- in, the human or other mammal for use in a method of treatment of pruritus in a, according to claim 1 pharmaceutical composition.  3. 3, 4 - Professional pinot perhydronaphthyl pudding is tricyclic, neo saki shi toxin, death carbamoyl saki shea toxin, antagonistic out relaxin or (GTX), in particular GTX-1, GTX-2, GTX-3, GTX-4, or in the GTX-5, pruritus in a human or other mammals for use in a method of treatment of, according to claim 1 or 2 pharmaceutical composition.  4. Where PSP, in its racemic form, the pure stereoisomers, especially enantiomers or in the form of a diastereomer, or mixture of stereoisomers, especially enantiomers or in the form of a mixture of diastereomers, neutral form, in the form of an acid or base, or salt, in the form of a physiologically acceptable salt, or solvate thereof, in particular in the form of a monohydrate, in a human or other mammal for use in a method of treatment of itching, wherein any one of claims 1-3 pharmaceutical composition.  5. Where PSP, saxitoxin, neo saki shi toxin, death carbamoyl saki shea toxin, or GTX, particularly GTX-1, GTX-2, GTX-3, GTX-4, or GTX-5 and, wherein the saxitoxin, neo saki shi toxin, death carbamoyl saki shea toxin, or GTX, particularly GTX-1, GTX-2, GTX-3, GTX-4, or GTX-5 is, or are synthetically synthesized, isolated from a biological source, in particular from plasfocjanin, dinoflagellate alga from, or a shellfish from contamination, particularly contaminated A. catenella and isolated from shellfish, in a human or other mammal for use in a method of treatment of itch, according to any one of claims 1-4 pharmaceutical composition.  6. Where PSP, - 1000μg/day for days 0.01μg /, in particular 0.1-100μg/day, and more particularly in an amount of saxitoxin 1-10μg/day, neo saki shi toxin, death carbamoyl saki shea toxin, or GTX, particularly GTX-1, GTX-2, GTX-3, GTX-4, or in the GTX-5, in a human or other mammal for use in a method of treatment of itching, wherein any one of claims 1-5 pharmaceutical composition.  7. Where PSP, professional pinot perhydronaphthyl pudding and the tricyclic 3, 4 -, 3, 4 - tri-professional pinot perhydronaphthyl pudding is, or is combined with the synthesis, or is isolated from a biological source, in a human or other mammal for use in a method of treatment of itch, according to any one of claims 1-6 pharmaceutical composition.  8. Itching, itching of the sensitive properties, the properties of a nerve, the properties of a neurological disorder, a psychogenic Seishitsu, due to inflammatory processes, due to insect bites, inflammatory processes, healing inflammation due to surgery or in particular according to the processes, infectious processes, in particular viral, bacterial, or fungal infections caused by prions by processes, pruritus induced by substance to circulate, systemic pathologies, acute or chronic renal failure or biliary particularly due to exposure to any allergen, exposure to tobacco, a smokeless tobacco due to exposure to a particular, due to exposure to a chemical substance, or is caused by respiratory causing, in a human or other mammal in itching for used in the treatment methods, according to any one of claims 1-7 pharmaceutical composition.  9. Where PSP, 7 January single use or for use over a period of time, for use in the treatment cycle a plurality of, and/or long-term treatment is for use, in a human or other mammal for use in a method of treatment of itching of, any one of claims 1-8 pharmaceutical composition.  10. Where PSP, skin patch, cream, ointment or spray by the use of, and/or a physical method by the use of the transdermal delivery, in particular ion permeation therapy, ultrasound permeation method, the macro poration, by adjusting temperature or magnetic, or physical device, in particular respiratory apparatus, in particular by the use of the sprayer, for use in a topical administration, to a human or other mammal for use in a method of treatment of pruritus in of, wherein any one of claims 1-9 pharmaceutical composition.  11. Claims 1-10 1 any one of the at least one of the two PSP, and a pharmacologically acceptable carrier, in a human or other mammal for use in a method of treatment of pruritus in a pharmaceutical composition, the pharmaceutical composition is prepared for topical administration, said pharmaceutical composition.  12. A PSP, 0 .01-1000μg, in particular 0.1-100μg, more particularly 1 to administering 1-10μg per PSP of in an amount suitable for, in a human or other mammal for use in a method of treatment of itch, pharmaceutical composition according to claim 11.  13. A PSP, 0 .01-1000μg/ml, in particular 0.1-100μg/ml, and more particularly in a concentration of 1-10μg/ml, in a human or other mammal for use in a method of treatment of itch, pharmaceutical composition according to claim 11 or 12.  14. For topical administration of the pharmaceutical composition is prepared, skin patch, cream, ointment, or spray is, in a human or other mammal for use in a method of treatment of itch, according to any one of claims 11-13 pharmaceutical composition.  15. The pharmaceutical composition further comprises, at least one antipruritic compound 1, in particular antihistamine compound, in particular kurorufenamin, loratadine or desloratadine, a corticosteroid, in particular betamethasone, clobetasol or mometasone, or a non-steroidal anti-inflammatory drug, in particular ibuprofen, diclofenac or ketoprofen comprising, in a human or other mammal for use in a method of treatment of itching, wherein any one of claims 11-14 pharmaceutical composition.  16. Where PSP, liposome or microemulsion and contains, and/or the pharmaceutical composition further, through the skin at least one PSP 1 promotes the transport of the material, in particular in comprises a material selected from the group consisting characterized in that, in a human or other mammal for use in a method of treatment of itch, according to any one of claims 11-15 pharmaceutical composition: an alcohol, amine, amide, amino acid, amino acid esters, substituted azacycloheptane - -2 - on 1 -, pyrrolidones, terpenes, fatty acids, fatty acid esters, macrocyclic compounds, surface active agent, a sulfoxide, a liposome, a transfersome, lecithin vesicle, etosomu, anionic, cationic and non-ionic surfactants, polyols, essential oil, dimethylsulfoxide, decylmethylsulfoxide, diethylene glycol monoethyl ether, diethylene glycol monomethyl ether, sodium laurate, sodium lauryl sulfate, cetyl trimethyl ammonium bromide, benzalkonium chloride, poloxamer, polysorbate 20 (polyoxyethylene sorbitan monolaurate), polysorbates (polyoxyethylene sorbitan monopalmitate) 40, polysorbate 60 (polyoxyethylene sorbitan monostearate), polysorbate 80 (polyoxyethylene sorbitan monooleate), lecithin, dodecyl sik raza cycloheptane on 1-n - -2 -, ethanol, propanol, octanol, benzyl alcohol, lauric acid, oleic acid, valeric acid, isopropyl myristate, isopropyl palmitate, Methylpropionic acid, ethyl oleate, sorbitan sesquioleate, propylene glycol, ethylene glycol, glycerol, butanediol, polyethylene glycol, polyethylene glycol monolaurate, urea, dimethylacetamide, dimethylformamide, 2 - - pyrrolidone, -2 - methyl 1 - - pyrrolidone, ethanolamine, diethanolamine, triethanolamine, alkanones, salicylic acid, salicylate salts, citric acid, and succinic acid.
法律状态
(JP6196638) LEGAL DETAILS FOR JP2015509971  Actual or expected expiration date=2033-03-15    Legal state=ALIVE    Status=GRANTED     Event publication date=2013-03-15  Event code=JP/APP  Event indicator=Pos  Event type=Examination events  Application details  Application country=JP JP2014561471  Application date=2013-03-15  Standardized application number=2014JP-0561471     Event publication date=2015-01-05  Event code=JP/A529  Event type=Corrections  Written submission of copy of amendment under section 34 (pct)  Effective date of the event=2014-11-17  JAPANESE INTERMEDIATE CODE: A529     Event publication date=2015-04-02  Event code=JP/A  Event indicator=Pos  Event type=Examination events  Published application  Publication country=JP  Publication number=JP2015509971  Publication stage Code=A  Publication date=2015-04-02  Standardized publication number=JP2015509971     Event publication date=2016-03-10  Event code=JP/A521  Event type=Restitution or restoration  Written amendment  Effective date of the event=2016-03-10  JAPANESE INTERMEDIATE CODE: A523     Event publication date=2016-03-10  Event code=JP/A621  Event indicator=Pos  Event type=Examination events  Written request for application examination  Effective date of the event=2016-03-10  JAPANESE INTERMEDIATE CODE: A621     Event publication date=2016-12-13  Event code=JP/A977  Event type=Examination events  Report on retrieval  Effective date of the event=2016-12-13  JAPANESE INTERMEDIATE CODE: A971007     Event publication date=2016-12-19  Event code=JP/A131  Event indicator=Neg  Event type=Examination events  Notification of reasons for refusal  Effective date of the event=2016-12-19  JAPANESE INTERMEDIATE CODE: A131     Event publication date=2017-03-21  Event code=JP/A601  Event type=Examination events  Written request for extension of term  Effective date of the event=2017-03-21  JAPANESE INTERMEDIATE CODE: A601     Event publication date=2017-05-19  Event code=JP/A601  Event type=Examination events  Written request for extension of term  Effective date of the event=2017-05-19  JAPANESE INTERMEDIATE CODE: A601     Event publication date=2017-06-16  Event code=JP/A521  Event type=Restitution or restoration  Written amendment  Effective date of the event=2017-06-16  JAPANESE INTERMEDIATE CODE: A523     Event publication date=2017-07-28  Event code=JP/TRDD  Event indicator=Pos  Event type=Administrative notifications  Trial decision date    Event publication date=2017-08-02  Event code=JP/A01  Event indicator=Pos  Event type=Event indicating In Force  Written decision to grant a patent or to grant a registration (utility model)  Effective date of the event=2017-08-02  JAPANESE INTERMEDIATE CODE: A01     Event publication date=2017-08-24  Event code=JP/A61  Event indicator=Pos  Event type=Event indicating In Force  First payment of annual fees (during grant procedure)  Effective date of the event=2017-08-18  JAPANESE INTERMEDIATE CODE: A61     Event publication date=2017-08-25  Event code=JP/R150  Event indicator=Pos  Event type=Event indicating In Force   Certificate of patent (=grant) or registration of utility model JAPANESE INTERMEDIATE CODE: R150     Event publication date=2017-09-13  Event code=JP/B2  Event indicator=Pos  Event type=Event indicating In Force  Published granted patent (Second level)  from 01-03-1996 onwards (Published examined patent application (Second level) 1971-1996)  Publication country=JP  Publication number=JP6196638  Publication stage Code=B2  Publication date=2017-09-13  Standardized publication number=JP6196638
专利类型码
B2A
国别省市代码
若您需要申请原文,请登录。

最新评论

暂无评论。

登录后可以发表评论

意见反馈
返回顶部